Tobacco Industry Settles With States

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 12
Volume 7
Issue 12

WASHINGTON-As Oncology News International went to press, the tobacco industry and more than 40 state attorneys general were in final negotiations of a settlement worth approximately $206 over 25 years. The settlement will reimburse the states for Medicare spending on smoking-related illnesses, place some limits on cigarette advertising, and result in a substantial increase in cigarette prices. Look for a full analysis of the settlement in the January issue.

WASHINGTON—As Oncology News International went to press, the tobacco industry and more than 40 state attorneys general were in final negotiations of a settlement worth approximately $206 over 25 years. The settlement will reimburse the states for Medicare spending on smoking-related illnesses, place some limits on cigarette advertising, and result in a substantial increase in cigarette prices. Look for a full analysis of the settlement in the January issue.

Articles in this issue
Long-Term Adjuvant Tamoxifen Urged for Low-Risk Breast Cancer
EORTC DCIS Study Confirms Recurrence Reduction With RT
James Cancer Center Joins NCCN Outcomes Database
Managed Care Sees Need for National Guidelines, Accreditation
Advisory Panel Recommends Approval of Vysis HER2 Test
Drinking Tea After Smoking May Reduce Oxidative Stress
Roswell Park and Local HMO Use Claims Data to Study Regional Breast Cancer Care Patterns to Evaluate Quality
Use Special Skills, Tools to Assess Pain in Children, Elderly
Good Response Rates With Radiolabeled Anti-CD20 MoAB in NHL
Tobacco Industry Settles With States
Komen Foundation 1998 Awards Honor Leaders in Fight Against Breast Cancer
Dose Intensity, Density Increased in Breast Cancer
Full FDA Approval for Camptosar
CRFA Presents Frontlines Awards for Breast Cancer Awareness
Panel Recommends FDA Approval of DepoCyt
Recent Videos
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content
IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer

IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer

Russ Conroy
October 28th 2024
Article

Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

ONCOLOGY Staff
October 27th 2024
Article

A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Evaluating Immunotherapy Options Based on Mutations for NSCLC

Evaluating Immunotherapy Options Based on Mutations for NSCLC

ONCOLOGY Staff
October 26th 2024
Article

Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC.

Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.

DLL3-Targeted ADC Produces Responses in Previously Treated ES-SCLC

Russ Conroy
October 25th 2024
Article

Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.